{
    "label": "Is this request for starting or continued therapy with Wegovy™ (semaglutide)?",
    "node_type": "fieldset",
    "children": [
        {
            "label": "Initial review criteria",
            "outcome": "The requested drug, Wegovy™ (semaglutide), is expected to be covered with prior authorization for 3 months",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Prescribed by Endocrinologist or Weight Management Specialist",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Patient at least 18 years of age",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Baseline BMI 30 kg/m2 or greater with at least one of the following weight-related comorbidities:",
                    "node_type": "checkbox",
                    "node_value": false,
                    "children": [
                        {
                            "label": "Established cardiovascular disease or stroke",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Hypertension",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Type 2 DM",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "CKD",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "CHD",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Obstructive sleep apnea",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Polycystic ovarian syndrome",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Dyslipidemia",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Non-alcoholic fatty liver disease",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Idiopathic intracranial hypertension",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Osteoarthritis in weight-bearing joints",
                            "node_type": "checkbox",
                            "node_value": false
                        }
                    ]
                },
                {
                    "label": "Documented baseline weight",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Patient has attempted to lose weight through a KP-approved weight loss program, and will continue these interventions while on Wegovy",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Patient has documented intolerance, contraindication or failure to lose and maintain greater than or equal to 5% body weight after a 3-month trial of ALL of the following medications indicated for chronic weight management:",
                    "node_type": "checkbox",
                    "node_value": false,
                    "all_required": true,
                    "children": [
                        {
                            "label": "Xenical (orlistat)",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Contrave (naltrexone + bupropion)",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Qsymia (phentermine + topiramate)",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Saxenda (liraglutide)",
                            "node_type": "checkbox",
                            "node_value": false
                        }
                    ]
                },
                {
                    "label": "Wegovy is not being used in combination with another weight loss drug or GLP-1 receptor agonist",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Initial prescription is limited to a maximum of 30-day supply with 2 refills",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "For patients with Type 2 DM and BMI of 30 kg/m2 or greater, must meet both additional criteria below:",
                    "node_type": "checkbox",
                    "node_value": false,
                    "all_required": true,
                    "children": [
                        {
                            "label": "Must follow KP National Adult DM Guidelines and CBC step therapy criteria for use of preferred agents for DM control",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Documented intolerance, contraindication, or failure to reach goal A1c after at least 6 month trial of Victoza and Ozempic",
                            "node_type": "checkbox",
                            "node_value": false
                        }
                    ]
                }
            ]
        },
        {
            "label": "Continuation of therapy",
            "outcome": "The requested drug, Wegovy™ (semaglutide), is expected to be covered with prior authorization for 6 months",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Patient continues to meet initial review criteria",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Documented weight loss within the previous 3 months of at least 10% from baseline weight",
                    "node_type": "checkbox",
                    "node_value": false
                }
            ]
        }
    ]
}